Leucocyte adherence inhibition for detecting specific tumour immunity in early pancreatic cancer.
Tumour-specific immunity to pancreatic tumour antigens, assayed by an automated tube leucocyte-adherence inhibition assay (L.A.I.), was detected in 3 of 3 patients with localised pancreatic cancer and 3 of 8 patients with more extensive pancreatic cancer. Leucocytes from pancreatic cancer patients with L.A.I. reactivity did not react to antigens of stomach, colon, or lung tumours; leucocytes from patients with stomach, colon, or lung cancer of inflammatory disease of the pancreas and bowel did not show L.A.I. reactivity to pancreatic tumour antigens.
D007516:Adenoma, Islet Cell / Q000175:diagnosis / Q000276:immunology*; D000951:Antigens, Neoplasm; D003110:Colonic Neoplasms / Q000276:immunology; D006801:Humans; D007962:Leukocytes / Q000276:immunology*; D008175:Lung Neoplasms / Q000276:immunology; D010181:Pancreatic Cyst / Q000276:immunology; D010190:Pancreatic Neoplasms / Q000175:diagnosis / Q000276:immunology*; D010195:Pancreatitis / Q000276:immunology; D013274:Stomach Neoplasms / Q000276:immunology; D013997:Time Factors
D000951:Antigens, Neoplasm